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Low Serum Homoarginine Is a Novel Risk Factor for Fatal
Strokes in Patients Undergoing Coronary Angiography
Stefan Pilz, MD; Andreas Tomaschitz, MD; Andreas Meinitzer, PhD; Christiane Drechsler, MD, PhD;
Eberhard Ritz, MD; Vera Krane, MD; Christoph Wanner, MD;
Bernhard O. Böhm, MD; Winfried Ma¨rz, MD
Background and Purpose—Low serum concentrations of the amino acid homoarginine have been associated with
endothelial dysfunction and an increased risk of all-cause and cardiovascular mortality. We aimed to investigate whether
homoarginine levels are also associated with fatal strokes and a history of nonfatal cerebrovascular disease.
Methods—Serum homoarginine was measured in 3305 participants of the Ludwigshafen Risk and Cardiovascular Health
(LURIC) study who were referred to coronary angiography at baseline (1997 to 2000) and were followed up with respect
to mortality.
Results—During a median follow-up time of 9.9 years, 991 patients died including 61 fatal (ischemic and hemorrhagic)
strokes. In a binary logistic regression analysis, the odds ratio (with 95% CI) for fatal stroke per SD of homoarginine
was 0.52 (0.37 to 0.73; P0.001) and remained significant after multivariable adjustments (0.62 [0.42 to 0.91];
P0.014). For previous cerebrovascular disease events, the multivariable adjusted OR per SD of homoarginine was 0.82
(0.70 to 0.96; P0.014).
Conclusions—Low homoarginine levels are a novel risk factor for fatal strokes and are reduced in patients with a history
of cerebrovascular disease. Further studies are needed to explore the significance of homoarginine to risk stratification
and therapeutic approaches in the prevention of strokes. (Stroke. 2011;42:1132-1134.)
Key Words: amino acids  cerebrovascular  homoarginine  mortality  prospective
Homoarginine is an amino acid that seems to be mainlysynthesized from lysine in the kidney.1 Previous studies
suggest a role of homoarginine in the metabolism of the
vasodilator nitric oxide.2–5 Homoarginine has been shown to
serve as a substrate for nitric oxide synthase and has been
associated with endothelial function.2 Homoarginine may
also play a role in insulin secretion, inhibition of platelet
aggregation, and blood pressure regulation.3–5 In the Lud-
wigshafen Risk and Cardiovascular Health (LURIC) study,
we have shown that low homoarginine concentrations are
associated with an increased risk of all-cause and cardio-
vascular mortality.6 These data among patients referred to
coronary angiography were confirmed by similar results in
hemodialysis patients.6 Whether homoarginine levels are
also associated with risk of strokes has not been examined
so far. Hence, we investigated in the LURIC study whether
serum homoarginine levels are associated with risk of
strokes.
Methods
Baseline examinations of the LURIC cohort (1997 to 2000) and
follow-up procedures have been published previously with some
disease classifications being updated meanwhile.6,7 In brief, the
LURIC study consists of 3316 white patients who were referred to
coronary angiography at a tertiary care center in southwest Germany.
Written informed consent was obtained from all study participants
and the “A¨ rztekammer Rheinland-Pfalz” gave ethical approval for
the study. Previous cerebrovascular disease events were defined as a
documented history of a foregoing transient ischemic attack, pro-
longed ischemic deficit, or cerebral infarction. Serum homoarginine
was determined in 3305 study participants by means of a high-
performance liquid chromatography method, as previously de-
scribed.6 Binary logistic regression analyses of patients with fatal
stroke versus the remaining study cohort were performed with the
SD of homoarginine (derived from the entire cohort) as an explan-
atory (independent) variable. Several possible confounders including
established risk factors of stroke were stepwise included as
indicated.8 Similarly, we calculated logistic regression analyses
with a dichotomous outcome variable for the presence or absence
of a history of cerebrovascular disease events at baseline. Statis-
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tical analyses were performed by SPSS Version 17.0 (SPSS Inc,
Chicago, IL) and a probability value 0.05 was considered
statistically significant.
Results
The homoarginine concentration (meanSD) in the entire
LURIC cohort was 2.421.05 mol/L. Baseline characteris-
tics are shown in Table 1. During a median follow-up period
of 9.9 years, 991 patients died including 61 fatal strokes. In a
binary logistic regression analysis, the OR (with 95% CIs) for
fatal stroke per SD of homoarginine was 0.52 (0.37 to 0.73;
P0.001). This association remained statistically significant
after adjustments for various possible confounders (Table 2).
Unadjusted OR for a previous (nonfatal) cerebrovascular
disease event at baseline (n302) per SD of homoarginine
was 0.67 (0.58 to 0.78; P0.001). After multivariable adjust-
ments (according to Model 4 in Table 2), this association
remained significant with 0.82 (0.70 to 0.96; P0.014).
Discussion
In patients referred to coronary angiography, we show that
low serum homoarginine levels are an independent risk factor
for fatal strokes and a history of cerebrovascular disease
events.
A previous analysis of the LURIC cohort with a shorter
follow-up time has shown that low homoarginine predicts
mortality.6 The current work is the first report on the
association of homoarginine status and stroke risk. Underly-
ing mechanisms remain to be explored but there exists
accumulating evidence that homoarginine plays a role in the
metabolism of nitric oxide, which is critically involved in the
regulation of cerebral blood flow and cell viability.9 Further
studies suggest that homoarginine might play a role in the
pathogenesis of stroke risk factors such as diabetes mellitus,
arterial hypertension, or prothrombotic states.3–6 Interest-
ingly, the key enzyme for homoarginine synthesis, arginine:
glycine amidinotransferase, is upregulated in the failing heart
and is highly expressed in the brain.1,10 Inborn errors of this
enzyme lead to disturbances in energy metabolism, so-called
creatine deficiency syndromes, which are associated with
mental disorders.11
Our data are limited by the relatively low number of
events, which preclude adequately powered analyses of
specific causes of stroke deaths. Furthermore, we investigated
a specific cohort of patients referred to coronary angiography
and our results may not be generalizable. Despite careful
adjustments for possible confounders, we cannot rule out
residual confounding.
In summary, our results suggest that low serum ho-
moarginine levels are a novel risk factor for strokes.
Further studies are needed to elucidate whether homoargi-
nine levels may help to improve risk prediction of strokes
and whether homoarginine is a promising target for ther-
apeutic approaches.
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